Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Rucaparib & Fallopian Tube Cancer, the US FDA has approved rucaparib as maintenance therapy for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in a complete or partial response to platinum‑based chemotherapy. This approval is based on the phase III ARIEL3 trial, which included patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
The European Medicines Agency (EMA) markets rucaparib, indicated as monotherapy for advanced (FIGO III–IV) high‑grade epit…